Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Bloomberg Scarce Resources UCTS ETF 19.12.2025 SCAR LN IE000BW2B3J3 25,002.00 USD 672,170.61 26.885  ...

TOKIO--(BUSINESS WIRE)--Incyte Biosciences Japan G.K. maakte vandaag bekend dat het Japanse MHLW (Ministry of Health, Labour & Welfare) Minjuvi® (tafasitamab) in combinatie met rituximab en lenalidomide heeft goedgekeurd voor volwassen patiënten met gerecidiveerd of refractair folliculair lymfoom (2L+ FL). “De goedkeuring van vandaag voor Minjuvi in combinatie met rituximab en lenalidomide betekent een belangrijke mijlpaal als eerste dubbel gerichte CD19 en CD20 immunotherapiecombinatie ter...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share FIRST TRUST INDXX FUTURE ECONOMY METALS UCITS ETF 19.12.2025 METL LN IE000UDFKE13 75,002.00 USD 2,308,272.67 30.776  ...

HAMBURG, Germany--(BUSINESS WIRE)--XCharge is cooperating in testing with EnBW on their fast-charging-network, the EnBW HyperNet in Germany. Since August 2025, EnBW has deployed one charger to complement a location near Stuttgart. Now, an important step in the collaboration was made and a field test with 10 charging stations at four different locations has started. The test includes two XCharge units at EnBW’s site in EnBW City in Stuttgart and three other sites; Rutesheim, Karlsruhe (Durlach C...

TOKYO--(BUSINESS WIRE)--Incyte Biosciences Japan G.K. ha annunciato oggi l'approvazione da parte del Ministero giapponese della Salute, del Lavoro e del Welfare (MHLW) di Zynyz® (retifanlimab) in combinazione con carboplatino e paclitaxel (terapia chemioterapica a base di platino) per il trattamento di prima linea del carcinoma a cellule squamose in fase avanzata del canale anale (SCAC). "L'approvazione di oggi segna un importante traguardo per i pazienti affetti da cancro anale allo stadio ava...

TOKIO--(BUSINESS WIRE)--Incyte Biosciences Japan G.K. acaba de anunciar la aprobación por parte del Ministerio de Salud, Trabajo y Bienestar de Japón (MHLW) de Zynyz® (retifanlimab) en combinación con carboplatino y paclitaxel (quimioterapia basada en platino) para los tratamientos de primera línea del carcinoma escamoso avanzado del canal anal (SCAC). «La aprobación por parte del MHLW de Zynyz como el primer y único tratamiento de primera línea para el SCAC marca un importante hito para los pa...

CARMEL, Ind. & ROCKY HILL, Conn.--(BUSINESS WIRE)--Connie, Connecticut’s state-designated Health Information Exchange (HIE), is implementing Clinical Architecture’s PIQXL Gateway to help healthcare organizations across Connecticut assess and strengthen the quality of shared patient data. The solution enables Connie to evaluate incoming messages, identify where data quality breaks down, and provide participants with actionable insights. PIQXL Gateway is the first commercial solution built on the...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Low Duration Global Government Bond UCITS ETF 19.12.2025 FGOV LN IE00BKS2X200 33,638.00 GBP 496,009.40 16.825  ...

CHARLOTTE, N.C.--(BUSINESS WIRE)--Driven Brands Holdings Inc. (NASDAQ: DRVN) (“Driven Brands” or the “Company”) today announced the election of Timothy Johnson as an independent director to its Board of Directors, effective January 1, 2026. Upon his election, Johnson will also serve as a member of the Audit Committee. “We’re excited to expand our Board with the addition of Tim,” said Jonathan Fitzpatrick, Non-Executive Chair of the Board. “He brings leadership and financial expertise along with...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Momentum UCITS ETF 19.12.2025 FTMO.LN IE000CY30YV9 3,050,002.00 USD 77,013,902.71 25.250  ...